KNIMS - The Karolinska Neuroimmunology & Multiple Sclerosis Centre
The Karolinska Neuroimmunology & Multiple Sclerosis (KNIMS) centre is a collective of neurological clinical and preclinical research scientists working actively to:
(1) provide first-class medical care for individuals with neurological disorders
(2) to understand their underlying pathogenic mechanisms
(3) to develop diagnostic tools and therapeutic modalities for their improved diagnosis and treatment.
KNIMS – On target to making a difference in neurological diseases
Neuroimmunological diseases such as Multiple Sclerosis, Alzheimers’ Disease and Viral encephalomyelitis are serious diseases for which there is currently no cure and the existing therapies are only partially effective. With an aging population the incidence of neurological diseases is steadily rising. There is thus a great medical need for both understanding of the pathological processes that characterise these disease states, as well as development of new, more effective therapies to treat them. We need to do this NOW.
We are a collective of Principal Investigators, either employed as clinicians or as researchers, with a common interest in neuroimmunological diseases. We have complimentary expertise that encompass several aspects of neuroimmunology, ranging from clinical diagnosis and treatment of patients, molecular biology, immunology, virology and genetics. Together with national and international research and clinical networks we thus represent a powerful research force within the field of Neuroimmunology. We have the ambition to make a difference for patients with these diseases, BECAUSE WE CAN, we want to, and by working together we are stronger.
Our clinics are based at the Karolinska Hospitals at Solna and Huddinge in Stockholm. Our research groups belong to the Department of Clinical Neuroscience at Karolinska Institutet and are physically located at the Centre for Molecular Medicine at KS Solna. The close proximity of the clinics and the research labs make for an optimal scientific environment for our collaborative efforts.
Knowledge in molecular science applied in clinical development is the driving force for KNIMS. By analysing samples obtained from patients attending our clinics, we are able to identify research questions of interest and to formulate hypotheses which can be tested in our preclinical research models. If therapeutic targets are identified then new modalities can be devised and tested in a preclinical setting before translation back into the clinic. In this way the wheel of interactive clincially-driven research turns again and again.